122 Results for "

Factor Xa

" in MedChemExpress (MCE) Product Catalog:
Products (122)

122 Results for "Factor Xa" in MCE Product Catalog:

Cat. No.: HY-19517
CAS No.: 865451-66-7
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .
loading...
    loading...
Cat. No.: HY-182420
CAS No.: 1628182-40-0
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

DJT06001 is an orally active, highly selective Factor Xa inhibitor. DJT06001 shows inhibition with Ki of 0.99 nM, IC50 of 2.53 nM in prothrombinase complex and 3.33 nM in human plasma. DJT06001 dose-dependently prolongs PT and APTT, inhibits thrombus formation in vivo. DJT06001 can be used for the research of thromboembolic diseases .
loading...
    loading...
Cat. No.: HY-11090A
CAS No.: 292135-59-2
DPC423 is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 can be used for the study of anticoagulation of arterial thrombosis .
loading...
    loading...
Cat. No.: HY-18660S
Synonyms: PER977-d8 tetrahydrochloride diacetate
Ciraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
loading...
    loading...
Cat. No.: HY-P5107
CAS No.: 121052-30-0
Synonyms: LMWP; TDSP5
Target:  

VEGFR

Research Areas:  

Cancer

Low molecular weight protamine (LMWP;TDSP5) is a truncated arginine-rich protamine peptide, as well as a heparin/low-molecular-weight heparin antidote and a cell-penetrating delivery carrier. Low molecular weight protamine neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities, and also neutralizes anti-Xa activity of commercially available low-molecular-weight heparin preparations. Low molecular weight protamine translocates across mammalian cell membranes, delivers conjugated impermeable molecules across tumor tissues, enhances skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine can be used in studies related to colon adenocarcinoma, skin wounds and diabetic skin wounds .
loading...
    loading...
Cat. No.: HY-10280S
CAS No.: 1794812-00-2
YM-60828-d3 is the deuterium labeled YM-60828 (HY-10280). YM-60828 is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 inhibits thrombus formation and platelet aggregation. YM-60828 can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .
loading...
    loading...
Cat. No.: HY-106404
CAS No.: 205054-36-0
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

RPR 130737 is a selective, potent and competitive inhibitor for factor Xa with a Ki of 2.4 nM. RPR 130737 shows selectivity of more than 1000-fold over thrombin, activated protein C, plasmin, tissue-plasminogen activator and trypsin. RPR 130737 can prolong plasma activated partial thromboplastin time and prothrombin time. RPR 130737 shows no effect on platelet aggregation. RPR 130737 can be used for the research of cardiovascular disease, such as thrombosis .
loading...
    loading...
Cat. No.: HY-10264R
CAS No.: 480449-70-5
Synonyms: DU-176 (Standard)
Edoxaban (Standard) is the analytical standard of Edoxaban. This product is intended for research and analytical applications. Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
loading...
    loading...
Cat. No.: HY-125505A
CAS No.: 864295-20-5
Research Areas:  

Cardiovascular Disease

BI-11634 free base is an orally active factor Xa inhibitor and a CYP3A4 substrate. The apparent Km values for BI-11634 free base metabolism are 23 μM in human liver microsomes (HLMs) and 7.6 μM with recombinant CYP3A4. BI-11634 free base can be used for thromboembolic disease and CYP3A4-mediated drug metabolism research .
loading...
    loading...
Cat. No.: HY-180217
Target:  

TMPRSS6 Factor Xa

Research Areas:  

Cardiovascular Disease

WGU55 is a selective and potent reversible type II transmembrane serine protease TMPRSS6 inhibitor with a Ki of 12.15 nM. WGU55 inhibits TMPRSS6 activity with an IC50 of 138 nMin KEK293 cells. WGU55 has a Ki of 3510 nM (SI = 289) against the homologous protease matriptase and a Ki of 5.2 μM against the coagulation key protease Factor Xa. WGU55 can be used for the research of iron overload related diseases, such as hereditary hemochromatosis .
loading...
    loading...
Cat. No.: HY-Z4525
CAS No.: 2244103-96-4
Synonyms: EdoXaban N-oxide
Target:  

Drug Intermediate

Research Areas:  

Others

Edoxaban impurity 15 (Edoxaban N-oxide) is an impurity of Edoxaban (HY-10264). Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research.
loading...
    loading...
Cat. No.: HY-10264BR
CAS No.: 1229194-11-9
Synonyms: DU-176b monohydrate (Standard)
Edoxaban tosylate monohydrate (Standard) is the analytical standard of Edoxaban tosylate monohydrate (HY-10264B). This product is intended for research and analytical applications. Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .
loading...
    loading...
Cat. No.: HY-11090
CAS No.: 209957-47-1
DPC423 free base is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 free base exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 free base blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 free base can be used for the study of anticoagulation of arterial thrombosis .
loading...
    loading...
Cat. No.: HY-179708
CAS No.: 3086979-57-6
Research Areas:  

Infection

Cbz-QFR-kbt is a ketone-based benzothiazole ketone inhibitor of TMPRSS2, with an IC50 value of 0.42 nM. Cbz-QFR-kbt also has inhibitory activity against Matriptase, Hepsin, HGFA, and Factor Xa, with IC50 values of 1, 1.3, 85, and 85 nM respectively. Cbz-QFR-kbt shows significant inhibitory effects against SARS-CoV-2 and H1N1 (IC50 = 60 nM). Cbz-QFR-kbt can be used in antiviral research .
loading...
    loading...
Cat. No.: HY-P6023
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

D-Leu-Pro-Arg-Rh110-D-Pro is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro can be used to detect FXIa activity .
loading...
    loading...
Cat. No.: HY-P6023B
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

D-Leu-Pro-Arg-Rh110-D-Pro acetate is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro acetate consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro acetate can be used to detect FXIa activity .
loading...
    loading...
Cat. No.: HY-P6023A
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro TFA consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro TFA can be used to detect FXIa activity .
loading...
    loading...
Cat. No.: HY-W145053
CAS No.: 149358-73-6
Synonyms: Sodium chloro(4-methylbenzenesulfonyl)azanide hydrate
Target:  

Factor Xa Bacterial

Research Areas:  

Infection

ChloraMine-T hydrate (Sodium chloro(4-methylbenzenesulfonyl)azanide (hydrate)) is a common reagent in various synthetic processes. It has been used as a reagent in aminohydroxylation and allylic amination reactions, a nitrogen source in aziridination reactions of alkenes and alkenes, and deprotection of sulfur groups in sulfur-containing compounds. It has been used as a reagent in the synthesis of factor Xa inhibitors. ChloraMine-T hydrate (Sodium chloro(4-methylbenzenesulfonyl)azanide (hydrate)) (0.2% w/v) is also an antimicrobial agent that kills Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Proteus mirabilis, and Enterococcus cloacae.
loading...
    loading...
Cat. No.: HY-135541
CAS No.: 365462-24-4
Synonyms: YM150 maleate
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

Darexaban maleate (YM150 maleate) is a direct factor Xa inhibitor with activity in preventing venous thromboembolism. The major metabolite of Darexaban maleate in humans is Darexaban glucitol, which acts pharmacologically. The glucitolation reaction of Darexaban maleate is mainly catalyzed by UGT1A9 and UGT1A10 in the human liver and intestine. The K(m) value of Darexaban maleate glucitolation in the liver is greater than 250 μM, while in the intestine it exhibits substrate inhibition kinetics with a K(m) value of 27.3 μM. The unbound K(m) value of Darexaban maleate is significantly reduced by the influence of fatty acid-free bovine serum albumin in both HLM and UGT1A9 .
loading...
    loading...
Cat. No.: HY-B0385R
CAS No.: 56974-61-9
Synonyms: FOY (Standard)
Gabexate (mesylate) (Standard) is the analytical standard of Gabexate (mesylate). This product is intended for research and analytical applications. Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .
loading...
    loading...